The patent for obinutuzumab, US7517670, was filed by Biogen Ideation Inc. and is listed under the United States Patent and Trademark Office [1]. This patent, titled "Humanized antibodies to CD20" and filed on March 26, 2004, covers a humanized antibody that binds to CD20 and its use in treating B-cell malignancies [2].
What is obinutuzumab?
Obinutuzumab is a monoclonal antibody that targets the CD20 protein found on the surface of B cells [3]. It is used in combination with chemotherapy to treat certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia [4]. The antibody is designed to deplete these malignant B cells, thereby controlling the cancer [3].
What does US7517670 patent cover?
Patent US7517670 specifically claims a humanized antibody that binds to CD20. It also covers methods of using such an antibody for treating a B-cell surface antigen-positive malignancy, including certain types of lymphoma and leukemia [2]. The patent details the composition and therapeutic applications of this antibody.
Who manufactures obinutuzumab?
Obinutuzumab is marketed under the brand name Gazyva by Genentech, a member of the Roche Group [4]. Genentech is the primary manufacturer and distributor of the drug [3][4].
When does obinutuzumab patent protection expire?
The expiration date for patent US7517670 is not publicly detailed in the provided information. Patent terms can be complex, often including extensions based on regulatory review periods, but the original expiration is typically 20 years from the filing date [1][2].
What are the next steps after patent expiry for obinutuzumab?
Following the expiration of key patents, the market for obinutuzumab could potentially open to biosimilar versions. Companies may seek to develop and gain approval for biosimilar versions of obinutuzumab, which could lead to increased competition and potentially lower prices [5].
What is the difference between obinutuzumab and rituximab?
Both obinutuzumab and rituximab are monoclonal antibodies that target CD20 and are used to treat B-cell malignancies [6]. However, obinutuzumab is a Type II antibody, while rituximab is a Type I antibody. This structural difference leads to distinct mechanisms of action, with obinutuzumab showing enhanced direct cell killing and altered immune effector functions compared to rituximab [3][6]. Clinical trials have indicated that obinutuzumab, when used in combination therapies, can lead to deeper remissions and improved progression-free survival in certain patient populations [4][6].
What are the potential risks and side effects of obinutuzumab treatment?
Common side effects associated with obinutuzumab treatment include infusion-related reactions, low blood cell counts (neutropenia, thrombocytopenia, anemia), and infections [4]. More serious risks can include progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation, and bowel obstruction [4][7]. Patients and healthcare providers closely monitor for these adverse events during therapy.
Are there any ongoing legal challenges or patent disputes related to obinutuzumab?
Information regarding ongoing legal challenges or patent disputes specifically concerning US7517670 is not available in the provided data. However, patent litigation is common in the pharmaceutical industry, particularly as drug exclusivity periods near their end, with companies often challenging existing patents to facilitate the entry of generic or biosimilar products [5].
---
Sources:
1. https://patents.google.com/patent/US7517670
2. https://patents.google.com/patent/US7517670B2
3. https://www.roche.com/media/releases/med-20131104
4. https://www.gene.com/media/press-releases/display?dateOrId=5670e745-87e2-4e76-9b96-85419b3316c3
5. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/biosimilars
6. https://ashpublications.org/blood/article/122/21/3675/102057/Obinutuzumab-vs-rituximab-in-chronic-lymphocytic
7. https://www.janssen.com/sites/default/files/imce/documents/Gazyvaprescribinginformation.pdf